GLP-1 Agonists and Addiction: Can Ozempic Reduce Cravings?

When patients on GLP-1 receptor agonists began reporting spontaneously reduced interest in alcohol, nicotine, and even compulsive behaviors like gambling, researchers took notice. What started as anecdotal reports has evolved into one of the most active areas of addiction neuroscience research. The connection makes biological sense: GLP-1 receptors are densely expressed in the brain's reward circuitry, the same neural pathways hijacked by addictive substances.

The mesolimbic dopamine pathway — running from the ventral tegmental area (VTA) to the nucleus accumbens — is the core of the brain's reward system. Addictive substances increase dopamine signaling in this pathway, creating the reinforcing 'high.' GLP-1 receptors are expressed on neurons in both the VTA and nucleus accumbens. When activated by GLP-1 agonists like semaglutide, these receptors appear to modulate dopamine release, reducing the rewarding effects of substances without eliminating natural pleasure responses entirely. Think of it as turning down the volume on substance-related reward signals specifically.

The preclinical evidence is remarkably consistent across substances and species:

• Alcohol: Multiple studies show GLP-1 agonists reduce alcohol intake, preference, and relapse-like behavior in rodents and non-human primates. Mice with GLP-1 receptor knockouts in the nucleus accumbens drink more alcohol.
• Nicotine: GLP-1 agonists reduce nicotine self-administration and prevent nicotine-induced dopamine release in the nucleus accumbens.
• Cocaine and opioids: GLP-1 agonists reduce cocaine and opioid self-administration in rodent models and attenuate drug-seeking behavior after withdrawal.
• Food reward: The appetite-suppressing effects of GLP-1 agonists involve the same reward circuitry, suggesting a shared mechanism with substance-related cravings.

Large retrospective studies using electronic health records have found encouraging signals:

• A 2024 study in Nature Medicine analyzing 83,000+ patients found semaglutide users had 50-56% lower odds of new alcohol use disorder diagnoses compared to matched controls on other diabetes or obesity medications.
• Similar reductions have been observed for opioid use disorder, cannabis use disorder, and tobacco use disorder in observational analyses.
• These associations persist after controlling for weight loss, diabetes status, and other confounders, suggesting a direct neurological effect rather than a secondary benefit of weight loss.

The limitation: observational data cannot prove causation. Patients prescribed semaglutide may differ from controls in unmeasured ways.

Several prospective randomized controlled trials are now underway:

• SHIFT trial — Semaglutide for alcohol use disorder (University of North Carolina)
• Multiple NIH-funded trials — Evaluating GLP-1 agonists for smoking cessation, cocaine use disorder, and opioid use disorder
• Exenatide for alcohol dependence — A completed trial showing reduced alcohol consumption on fMRI and self-report measures

Results from these trials will determine whether GLP-1 agonists become a new class of addiction medication. If positive, they could represent the most significant advance in addiction pharmacotherapy since naltrexone and buprenorphine.

As of now, no GLP-1 agonist is FDA-approved for any substance use disorder. Prescribing semaglutide specifically for addiction is off-label and premature without prospective trial data. However, for patients who happen to be on semaglutide for diabetes or weight management and also have substance use issues, clinicians should be aware that reduced substance cravings may be a beneficial side effect. This is not a reason to prescribe semaglutide for addiction alone, but it's a reason to monitor and document these effects in patients who are already on it.

Patient reports consistently describe several patterns:

• 'I just stopped thinking about drinking.' — Reduced intrusive thoughts about substances
• 'I can have one drink and stop.' — Reduced loss of control over substance use
• 'Alcohol doesn't give me the same buzz.' — Reduced rewarding effects of substances
• 'I don't get the same craving when I drive past the liquor store.' — Reduced cue-triggered cravings

These reports align with the proposed mechanism of reduced reward signaling rather than aversion (which is how disulfiram/Antabuse works) or opioid blockade (how naltrexone works).